The DOI matches its Crossref record; 24 of the 24 references it cites were found in a registry or an index.
IL-12 Plasmid Delivery by in Vivo Electroporation for the Successful Treatment of Established Subcutaneous B16.F10 Melanoma
Open accessAbstract
Interleukin-12 (IL-12) has been used in numerous immunotherapy protocols against melanoma. However, delivery of IL-12 in the form of recombinant protein can result in severe toxicity, and gene therapy has had limited success against B16.F10 murine melanoma. The purpose of this study was to examine the effectiveness of in vivo electroporation for the delivery of plasmid DNA encoding IL-12 as an antitumor agent against B16.F10 melanoma. We treated mice bearing established B16.F10 melanoma tumors with intratumoral (i.t.) or intramuscular (i.m.) injections of a plasmid encoding IL-12, followed by in vivo electroporation. For i.t. treatments, we used an applicator containing six penetrating electrodes to deliver 1500-V/cm, 100-micros pulses. We administered i.m. pulses with an applicator containing four penetrating electrodes delivering 100-V/cm, 20-ms pulses. The i.t. treatment resulted in the cure of 47% of tumor-bearing mice, and 70% of cured mice were resistant to challenge with B16.F10 cells. The i.m. treatment did not result in tumor regression. We found that i.t. treatment resulted in increased levels of IL-12 and interferon-gamma (IFN-gamma) within the tumors, the influx of lymphocytes into the tumors, and reduction in vascularity. Neither i.m. nor i.t. treatment was successful against B16.F10 tumors in a nude mouse model, supporting a role for T cells in regression of this tumor model.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Antitumor and antimetastatic activity of interleukin 12 against murine tumors.
Brunda, M. J., Luistro, L., Warrier, R. R., Wright, R. B., Hubbard, B. R., Murphy, M., Wolf, S. F., & Gately, M. K. (1993) · The Journal of experimental medicine · doi:10.1084/jem.178.4.1223 · Cited by 1,197
Gene transfer into muscle by electroporation in vivo
Aihara, H., & Miyazaki, J.-I. (1998) · Nature Biotechnology · doi:10.1038/nbt0998-867 · Cited by 944
High-efficiency gene transfer into skeletal muscle mediated by electric pulses
Mir, L. M., Bureau, M. F., Gehl, J., Rangara, R., Rouy, D., Caillaud, J.-M., Delaere, P., Branellec, D., Schwartz, B., & Scherman, D. (1999) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.96.8.4262 · Cited by 914
In vivo gene electroinjection and expression in rat liver
Heller, R., Jaroszeski, M., Atkin, A., Moradpour, D., Gilbert, R., Wands, J., & Nicolau, C. (1996) · FEBS Letters · doi:10.1016/0014-5793(96)00590-x · Cited by 430
Self-citationIn vivo electrically mediated protein and gene transfer in murine melanoma
Rols, M.-P., Delteil, C., Golzio, M., Dumond, P., Cros, S., & Teissie, J. (1998) · Nature Biotechnology · doi:10.1038/nbt0298-168 · Cited by 421
In vivo electroporation and stable transformation of skin cells of newborn mice by plasmid DNA
Titomirov, A. V., Sukharev, S., & Kistanova, E. (1991) · Biochimica et Biophysica Acta (BBA) - Gene Structure and Expression · doi:10.1016/0167-4781(91)90162-f · Cited by 405
Niu, G., Heller, R. F., Catlett-Falcone, R., Coppola, D., Jaroszeski, M. J., Dalton, W. S., Jove, R., & Yu, H. (1999) · PubMed · Cited by 312
Self-citationClinical applications of electrochemotherapy
Heller, R., Gilbert, R., & Jaroszeski, M. J. (1999) · Advanced Drug Delivery Reviews · doi:10.1016/s0169-409x(98)00067-2 · Cited by 201
Self-citationAmount of interleukin 12 available at the tumor site is critical for tumor regression.
Colombo, M. P., Vagliani, M., Spreafico, F., Parenza, M., Chiodoni, C., Melani, C. C., & Stoppacciaro, A. (1996) · PubMed · Cited by 174
Role of Interferon-γ in Mediating the Antitumor Efficacy of Interleukin-12
Brunda, M. J., Luistro, L., Hendrzak, J. A., Fountoulakis, M., Garotta, G., & Gately, M. K. (1995) · Journal of Immunotherapy · doi:10.1097/00002371-199502000-00001 · Cited by 164
Novel electrode designs for electrochemotherapy
Gilbert, R. A., Jaroszeski, M. J., & Heller, R. (1997) · Biochimica et Biophysica Acta (BBA) - General Subjects · doi:10.1016/s0304-4165(96)00119-5 · Cited by 164
Self-citationToda, M., Martuza, R. L., Kojima, H., & Rabkin, S. D. (1998) · The Journal of Immunology · doi:10.4049/jimmunol.160.9.4457 · Cited by 161
Egilmez, N. K., Jong, Y. S., Sabel, M. S., Jacob, J. S., Mathiowitz, E., & Bankert, R. B. (2000) · PubMed · Cited by 143
Effective tumor therapy with plasmid-encoded cytokines combined with in vivo electroporation.
Lohr, F., Lo, D. Y., Zaharoff, D. A., et al. (2001) · PubMed · Cited by 134
Heller, L. C., Pottinger, C., Jaroszeski, M. J., Gilbert, R., & Heller, R. F. (2000) · Melanoma Research · doi:10.1097/00008390-200012000-00010 · Cited by 118
Self-citationElectrically mediated plasmid DNA delivery to hepatocellular carcinomas in vivo
Heller, L. C., Jaroszeski, M. J., Coppola, D., Pottinger, C., Gilbert, R., & Heller, R. F. (2000) · Gene Therapy · doi:10.1038/sj.gt.3301173 · Cited by 100
Self-citationKishida, T., Asada, H., Satoh, E., Tanaka, S., Shin‐Ya, M., Hirai, H., Iwai, M., Tahara, H., Imanishi, J., & Mazda, O. (2001) · Gene Therapy · doi:10.1038/sj.gt.3301519 · Cited by 98
Electroporation-enhanced gene delivery in mammary tumors
Wells, J. M., Li, L. H., Sen, A., et al. (2000) · Gene Therapy · doi:10.1038/sj.gt.3301141 · Cited by 92
Intradermal Delivery of Interleukin-12 Plasmid DNA by in vivo Electroporation
Heller, R. F., Schultz, J. G., Lucas, M. L., Jaroszeski, M. J., Heller, L. C., Gilbert, R. A., Moelling, K., & Nicolau, C. S. (2001) · DNA and Cell Biology · doi:10.1089/10445490150504666 · Cited by 85
Self-citationLucas, M. L., & Heller, R. F. (2001) · Molecular Therapy · doi:10.1006/mthe.2000.0233 · Cited by 75
Self-citationLong-Lasting Anti-Metastatic Efficiency of Interleukin 12-Encoding Plasmid DNA
Schultz, J. G., Pavlovic, J., Strack, B., et al. (1999) · Human Gene Therapy · doi:10.1089/10430349950018850 · Cited by 62
Yu, W., Ogawa, M., Mu, J., Umehara, K., Tsujimura, T., Fujiwara, H., & Hamaoka, T. (1997) · Journal of Leukocyte Biology · doi:10.1002/jlb.62.4.450 · Cited by 60
Marshall, E. (1995) · Science · doi:10.1126/science.268.5217.1555 · Cited by 57
Dabrowska, A., Giermasz, A., Marczak, M., Gołąb, J., & Jakóbisiak, M. (2000) · PubMed · Cited by 10
Cited by
Cytokines in clinical cancer immunotherapy
Berraondo, P., Sanmamed, M. F., Ochoa, M. C., Etxeberria, I., Aznar, M. A., Pérez-Gracia, J. L., Rodríguez-Ruiz, M. E., Ponz-Sarvise, M., Castañón, E., & Melero, I. (2019) · British Journal of Cancer · doi:10.1038/s41416-018-0328-y · Cited by 1,205
Phase I trial of interleukin-12 plasmid electroporation in patients with metastatic melanoma
Daud, A. I., DeConti, R. C., Andrews, S., Urbas, P., Riker, A. I., Sondak, V. K., Munster, P. N., Sullivan, D. M., Ugen, K. E., Messina, J. L., et al. (2008) · Journal of Clinical Oncology · doi:10.1200/jco.2007.15.6794 · Cited by 701
Self-citationNew insights into IL-12-mediated tumor suppression
Tugues, S., Burkhard, S. H., Ohs, I., Vrohlings, M., Nussbaum, K., vom Berg, J., Kulig, P., & Becher, B. (2015) · Cell Death & Differentiation · doi:10.1038/cdd.2014.134 · Cited by 558
Interleukin 12: still a promising candidate for tumor immunotherapy?
Lasek, W., Zagożdżon, R., & Jakobisiak, M. (2014) · Cancer Immunology Immunotherapy · doi:10.1007/s00262-014-1523-1 · Cited by 495
Localized Interleukin-12 for Cancer Immunotherapy
Nguyen, K. G., Vrabel, M. R., Mantooth, S. M., Hopkins, J. J., Wagner, E. S., Gabaldon, T. A., & Zaharoff, D. A. (2020) · Frontiers in Immunology · doi:10.3389/fimmu.2020.575597 · Cited by 431
Metadata
- Authors
- Lucas, M. L., Heller, L., Coppola, D., & Heller, R.
- Venue
- Molecular Therapy
- Publisher
- Elsevier BV
- Published
- 2002-06
- Volume
- 5
- Issue
- 6
- Pages
- 668-675
- ISSN
- 1525-0016 (ISSN-L)
- OpenAlex
- W2067738057
- Cited by
- 253
- References
- 24
- FWCI
- 11.46
- Type
- journal article
- Language
- en
- Open access
- hybrid
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.